The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce the tragic outcomes they cause, a large new study finds. An analysis published Wednesday in a medical journal looked at electronic health records from more than 600,000 U.S. Veterans Affairs patients with diabetes. It found that those treated with medications such as Ozempic and Mounjaro were less likely to develop addictions to alcohol, nicotine,